CVR 35234748Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)København NVFounded 1 May 2013
Employees
27
CVR registry, Aug 2026
+3 (+12.5%) over 12 months
Gross profit
47.6M
DKK, annual report 2025
+22% on 2024
Result
+11.1M
DKK, annual report 2025
Equity
18M
DKK, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about MACURE PHARMA ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexNest Egg ApSCVR 33876793, 100% of capital and votes, since 1 May 2013
Mads Renlef Henningsensince 5 Mar 2014
Lars Mark Poulsensince 1 Jan 2016
CVR 33876793100% of capital and votessince 1 May 2013
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
5 Mar 2014 to 1 Nov 2026.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 24,982 | 37,527 | 24,159 | 39,051 | 47,649 |
| Operating profit | +6,557 | +21,689 | +11,552 | +23,569 | +24,824 |
| Result for the year | +5,048 | +17,895 | +8,790 | +8,495 | +11,054 |
| Equity | 10,500 | 23,394 | 14,185 | 14,980 | 18,034 |
| Total assets | 100,485 | 114,206 | 170,273 | 202,510 | 162,202 |
| Employees (average) | 12 | 13 | 13 | 16 | 21 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | 64.9% | 50.2% | -36.5% | 61.6% | 22% |
| EBITDA | 6,710 | 21,827 | 12,805 | 24,007 | 26,021 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) | 26.9% | 58.2% | 53% | 61.5% | 54.6% |
| Employee growth (vækst i antal ansatte) | 20% | 8.3% | 0% | 23.1% | 31.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -9,384note 1 | -18,488note 1 | -43,077 | -16,750 | -11,805 |
| Gearing, NIBD / EBITDA | Net cashnote 1 | Net cashnote 1 | Net cash | Net cash | Net cash |
| ROIC (afkast af investeret kapital) | 200.5%note 1 | 560.9%note 1 | n.m.note 2 | n.m.note 2 | 867.8% |
| Capex (investeringer i anlægsaktiver) | 1,153note 3 | 5,151note 3 | 3,642note 4 | 5,434note 4 | 10,445note 4 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 22,971note 1 | 42,320note 1 | 88,110 | 134,844 | 63,113 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement: included in the group's (ÅRL § 86, stk. 4).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 26 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 26 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 19 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 6 Jul 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 29 Jun 2022
MACURE PHARMA ApS has changed ownership. A new strategy and new needs can be expected.
Signal, a Dandex estimate. Lapses 8 Jan 2027.
1 registered in CVR.
P-number 1018460129Hejrevej 39, 2400 København NV
